Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
00867 CMS
RTNominal down8.220 -4.320 (-34.450%)
Others

21/08/2019 14:30

{I-bank focus}Credit Suisse lifts CMS (00867) to HK$9.58

[ET Net News Agency, 21 August 2019] Credit Suisse lifted its target price for China
Medical System (CMS)(00867) to HK$9.58 from HK$9.1 and maintained its "outperform" rating.
The research house said CMS's 1H results slightly beat Credit Suisse's expectation,
mainly due to better-than-expected gross and net margin. Deanxit and Plendil's hospital
sales (60% of total sales) may face GPO pressure as early as 2H 2020, therefore, Credit
Suisse expects this segment to grow at 4-5% in the next three years.
CMS announced a new license agreement with Sun Pharma for the exclusive license to Sun
Pharma's seven generic products in mainland China for a minimum of 20 years. Credit Suisse
thinks it would further diversify its revenue sources to better reduce potential GPO
impact. It increased its 2019/20 net profit forecast by 2.4%/1.3% to factor in better 1H
profits. (KL)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.